EU closer to securing 200m doses of Johnson & Johnson Covid-19 vaccine

The talks follow the first agreement with Sanofi-GSK for 300m doses

The European Commission is closer to secure 200m doses of a possible vaccine against Covid-19, it announced on Thursday. The Commission has concluded exploratory talks with Janssen Pharmaceutica, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, in a step towards an advance purchase agreement, European Commission President Ursula von der Leyen and Health Commissioner Stella Kyriakides said.

This is following the first positive steps with Sanofi-GSK on 31 July to purchase 300m vaccine doses.

The envisaged contract with Johnson & Johnson would provide for the possibility for all EU Member States to purchase the vaccine, as well as to donate to lower and middle income countries or re-direct to EEA countries. It is anticipated that, once a vaccine has proven to be safe and effective against COVID-19, the Commission would have a contractual framework in place for the initial purchase of 200m doses on behalf of all EU Member States, and could further purchase up to an additional 200m vaccine doses. The Commission pursues intensive discussions with other vaccine manufacturers.

“Our citizens' lives and our economy need a safe and effective vaccine against the coronavirus. Today's talks bring us closer to achieving this. The Commission is making every effort, in close cooperation with the Member States and with pharmaceutical companies to actively contribute to this end,” Ursula von der Leyen said.

The vaccines are to be bought through an emergency support instrument funded with €2.7bn, created to establish a portfolio of potential vaccines with different profiles and made by different companies.

 

More on this subject: Coronavirus

Similar articles